(P-396) PREFER-LA: People with HIV (PWH) in the United States with Prior Adherence Challenges with Oral Antiretroviral Therapy (ART) Prefer Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) Therapy after Switch

Monday, October 20, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Presenting Author(s)

SK

Stephanie Kirk, PharmD

Clinical Associate Professor
Medical University of South Carolina
Charleston, South Carolina, United States
MB

Maurice Brownlee, APRN

Baal Perazim Wellness & Health Services Inc.
Chicago, Illinois, United States
MH

Matthew Herrmann, MD

Infectious Disease Specialist
Harbor-UCLA Medical Center
Sherman Oaks, California, United States
SZ

Sheryl Zayas, DO

Care Resource, Miami, FL
Miami, Florida, United States
KM

Katie L. Mycock, MChem

Associate Manager, Observational Research
Adelphi Real World
Bollington, England, United Kingdom
NR

Neil Reynolds, PhD

Adelphi Real World
Bollington, England, United Kingdom
HW

Hannah Wallis, MS

Adelphi Real World
Bollington, England, United Kingdom
MA

Mona Amet, MPH

Adelphi Real World
Bollington, England, United Kingdom
AL

Ann Linskey, PharmD, AAHIVP

ViiV Healthcare
Durham, North Carolina, United States
Jimena Patarroyo, PharmD, AAHIVP

Senior Medical Science Liaison
ViiV Healthcare
Research Triangle Park, North Carolina, United States
DM

Deanna Merrill, PharmD, MBA, AAHIVP

Medical Affairs Scientific Director, Research
ViiV Healthcare
Research Triangle Park, North Carolina, United States
EO

Edgar T. Overton, MD

Head Regional Medical Director
ViiV Healthcare
Birmingham, Alabama, United States
Cindy Garris, MS (she/her/hers)

Senior Director, US Health Outcomes
ViiV Healthcare
Durham, NC, United States
AB

Andrew P. Brogan, PhD

Director, US Health Outcomes
ViiV Healthcare
San Diego, California, United States